Cure Silk Honored with CES 2025 Digital Health Innovation Award
Medicosbiotech Inc., a global leader in spider silk protein production technology, has been awarded the CES 2025 Innovation Award in the Digital Health category at the world’s largest electronics and IT trade show, CES 2025. CES, which features participation from top global companies like Samsung and LG, bestows its Innovation Awards on products that demonstrate exceptional innovation, technological excellence, and design—often regarded as the highest honor at CES.
This recognition highlights Medicosbiotech’s groundbreaking technology and its unique fusion of AI and biotechnology. The award-winning product, an AI-driven medical application, aims to advance healthcare in underserved countries, enhance health outcomes for medically underserved populations, and reduce medical costs for U.S. payors.
AI-Based Application for Wound Diagnosis and Treatment : Cure Silk
Cure Silk is the world’s first treatment for chronic wounds incorporating spider silk protein. It is designed to address the treatment of stage 3-4 pressure ulcers and stage 5-6 diabetic foot ulcers, where there are no treatment. Medicosbiotech anticipates receiving Class II medical device approval from Korea’s Ministry of Food and Drug Safety in the first half of 2025.
Spider silk protein has long been recognized for its wound-healing properties, dating back 2,000 years in Europe when natural spider webs were used for treatment. However, its widespread adoption was hindered by the inability to mass-produce the protein. Medicosbiotech has overcome this challenge through synthetic biotechnology, successfully achieving mass production. With the dedication of CEO and plastic surgeon Wonmin Yoo, the development of spider silk-based wound care products for chronic wounds is nearing completion.
The Cure Silk App, the world’s first AI-driven intelligent wound care solution, diagnoses wounds by analyzing images captured via a camera and provides tailored solutions based on the wound type and severity. By integrating AI with biotechnology, this innovative app supports efficient home care for refractory wound treatment, even in remote settings. It is also expected to create a robust healthcare safety net for medically underserved populations in developing countries.
CEO Sooncheol Kim of Medicosbiotech remarked, “Cure Silk represents more than just technological innovation; it embodies the fusion of AI and biotechnology to fundamentally address healthcare inequities faced by underserved communities worldwide.”
Looking ahead, Medicosbiotech plans to lead the global medical and biotech markets by developing innovative biotechnologies and pursuing ESG-driven management, with a commitment to addressing global health disparities.
Media Contact
Company Name: Medicosbiotech Inc.
Contact Person: CEO SoonCheol Kim
Email:Send Email
Country: South Korea
Website: https://www.medicosbiotech.com/
